Hepatitis B vaccination after living donor liver transplantation

Yuji Soejima, Toru Ikegami, Akinobu Taketomi, Tomoharu Yoshizumi, Hideaki Uchiyama, Noboru Harada, Yoichi Yamashita, Yoshihiko Maehara

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: The efficacy of hepatitis B vaccination after living donor liver transplantation (LDLT) in patients transplanted anti-HBc-positive grafts or in patients who underwent LDLT for fulminant hepatitis B remains unknown. Method: A total of 11 recipients who underwent LDLT between October 1996 and October 2002 prospectively received hepatitis B vaccination three times within 6 months, starting a few weeks after the cessation of hepatitis B immunoglobulin (HBIG) prophylaxis. Serial quantification of the hepatitis B surface antibody (HBsAb) was performed. Results: At the last follow-up, six out of 11 patients (54.5%) had seroconversion and were free from HBIG thereafter. Four out of those six responders had a peak HBsAb level of more than 1000 IU/L, while the other two patients had peak HbsAb levels below 1000 IU/L. Five patients never responded to the treatment and were back to HBIG prophylaxis. The average age of the six responders was 25.5 years, which was significantly younger than that of non-responders (44.4 years, P < 0.05). None had side effects or hepatitis B infection during the study period. Conclusions: In conclusion, the use of this treatment modality could be used to reduce the cost of HBIG.

Original languageEnglish
Pages (from-to)977-982
Number of pages6
JournalLiver International
Volume27
Issue number7
DOIs
Publication statusPublished - Sep 1 2007

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this